Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lumasiran - Alnylam Pharmaceuticals

Next Previous
Drug Profile

Lumasiran - Alnylam Pharmaceuticals

Alternative Names: ALN-GO1; Lumasiran; Oxlumo

Latest Information Update: 27 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Class Amino sugars; Drug conjugates; Small interfering RNA; Uricosurics; Urologics
  • Mechanism of Action Glycolate oxidase expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary hyperoxaluria type 1
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Primary hyperoxaluria type 1
  • Phase II Urinary calculi

Most Recent Events

  • 27 Feb 2024 Registered for Primary hyperoxaluria type 1 in Qatar (SC) (Prior to February 2024)
  • 12 Jan 2024 Alnylam Pharmaceuticals completes the phase III ILLUMINATE-A trial for Primary hyperoxaluria type 1 (In adolescents, In children, In adults, In the elderly) in USA, France, Germany, Israel, Netherlands, Switzerland, United Arab Emirates and United Kingdom (NCT03681184)
  • 28 Apr 2023 Efficacy and adverse events data from a phase III ILLUMINATE-A trial in Primary hyperoxaluria type 1 presented at the 118th Annual Meeting of the American Urological Association (AUA-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top